The BioPharma industry is in rapid flux, shaped by transforming drug pipelines, the ongoing political battle over lowering drug prices, and a new rebate model for the 340B Drug Discount program. Here’s what’s shaping the latest in healthcare.
Source: BioPharma International
In a recent BioPharm International interview, Janice MacLennan, founder and CEO of Nmblr and senior strategy consultant to Big Pharma, discusses how defendable differentiation, AI, and a shift toward novel modalities are reforming biopharma R&D and commercialization.
Source: Fierce Healthcare
The Trump administration is reigniting debate over the 340B Drug Pricing Program with a new request for public input on a potential rebate-based pilot model. After a court-halted effort last year, the Health Resources and Services Administration (HRSA) is now seeking feedback on how such a shift could affect cash-flow, safety-net hospitals, and patient care. The deadline to weigh in is March 19.
Source: BioPharma Drive
Lawmakers are examining rising prescription drug costs and the roles that various players in the drug supply chain, manufacturers, PBMs, insurers, and others, may have in driving patient affordability challenges. During a recent House Energy and Commerce subcommittee hearing, members of both parties highlighted patients’ struggles with high prices, while also debating how recent federal health policies, funding cuts, and new initiatives like TrumpRx could affect coverage, innovation, and access to medicines. PBMs remained a particular focus, as legislators questioned market consolidation, transparency, and business practices amid ongoing efforts to reform the drug pricing system.
